dangers of bpc 157 FDA panel votes to ease restrictions on an unregulated peptide BPC-157 BPC-157: A Prohibited Peptide and

Journal of Physiology Paris 93:501504 Radeljak S, Seiwerth S, Sikiric P (2004) BPC 157 inhibits cell growth and VEGF signalling via the MAPK kinase pathway in the human melanoma cell line

Typically administered via subcutaneous injection in experimental settings, it is now available in a breakthrough capsule formula with high oral bioavailability

10.1111/j.1471-4159.2011.07442.x 46

Route: Intramuscular (IM) or subcutaneous (SubQ)

Research comparing BPC-157 to becaplermin (recombinant human platelet-derived growth factor, a FDA-approved wound healing agent) found that BPC-157 stimulated earlier maturation of granulation tissue and produced more organized collagen in wounds